The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Akums invested Rs. 272 crore in capital expenditure during FY25
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Subscribe To Our Newsletter & Stay Updated
